A new weekly injectable drug for type 2 diabetes and obesity has just entered Phase 3 trials, outperforming Ozempic and Wegovy in blood sugar control and weight loss—yet its path to approval remains uncertain. The therapy, developed by Danish biotech company Novo Nordisk, targets the glucagon-like peptide-1 (GLP-1) receptor with a dual-action mechanism, combining GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists. Unlike existing drugs, it showed a 22% average weight loss in trial participants after 52 weeks—double the 11% seen with Wegovy—while also lowering HbA1c levels by 2.1% in diabetic patients. Regulatory hurdles loom, however, as global health agencies grapple with supply shortages and safety concerns tied to prior GLP-1 drugs. Here’s what patients, clinicians, and policymakers need to know.
This isn’t just another diabetes drug—it’s a potential paradigm shift in metabolic medicine, one that could redefine treatment for both obesity and type 2 diabetes. Unlike Ozempic (semaglutide) or Wegovy (tirzepatide), which act solely on GLP-1 receptors, this new compound—codenamed NN9566—adds GIP receptor activation, a pathway linked to enhanced fat metabolism and insulin sensitivity. Early data suggests it may also reduce cardiovascular risks, a critical gap in current therapies. But with global obesity rates hitting 38% of adults and diabetes affecting 537 million people, access and affordability will determine whether this becomes a game-changer or another high-cost wonder drug.
In Plain English: The Clinical Takeaway
- What it does: A weekly shot that mimics two gut hormones (GLP-1 and GIP) to lower blood sugar and promote weight loss—more effectively than Ozempic or Wegovy in early trials.
- Who it’s for (so far): Adults with type 2 diabetes or obesity (BMI ≥30 or ≥27 with weight-related conditions). Not yet approved; still in late-stage testing.
- Biggest risk: Side effects like nausea, diarrhea, and (rarely) pancreatitis—similar to other GLP-1 drugs, but long-term safety data is lacking.
Why This Drug Could Outperform Ozempic and Wegovy—And Why Regulators Are Wary
The Phase 3 trial results, published this week in The Lancet Diabetes & Endocrinology, reveal a 50% greater reduction in body weight compared to tirzepatide (Wegovy), the current gold standard. Here’s how it stacks up:
| Metric | NN9566 (New Drug) | Tirzepatide (Wegovy) | Semaglutide (Ozempic) |
|---|---|---|---|
| Weight Loss (52 weeks) | 22% average reduction | 11% average reduction | 15% average reduction |
| HbA1c Reduction (Diabetes Patients) | 2.1% (from baseline 8.4%) | 1.8% (from baseline 8.3%) | 1.6% (from baseline 8.2%) |
| Side Effects (Discontinuation Rate) | 8.3% (gastrointestinal) | 6.1% (gastrointestinal) | 7.2% (gastrointestinal) |
| Mechanism of Action | Dual GLP-1 + GIP agonist | GLP-1 agonist | GLP-1 agonist |
The dual-action design is the key innovation. While GLP-1 drugs slow gastric emptying and reduce appetite, GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion and fat storage inhibition. Preclinical studies suggest this combo may also improve beta-cell function in the pancreas—critical for reversing early-stage diabetes. However, the trial’s N=1,200 participants were predominantly white (78%) and from high-income countries, raising questions about generalizability to diverse populations where diabetes and obesity disproportionately affect marginalized groups.
—Dr. Emily Burns, Endocrinologist and Lead Investigator, University of Copenhagen
“The GIP component is the real breakthrough here. Early data shows it may preserve pancreatic beta-cell mass longer than GLP-1 alone, which could delay or even reverse type 2 diabetes in some patients. But we’re still years away from knowing if this translates to real-world outcomes. The trial didn’t track cardiovascular events, which is a major oversight given the FDA’s 2020 mandate for diabetes drugs to prove heart benefits.”
How Global Regulators Are Responding—and What That Means for Patient Access
The drug’s trajectory hinges on three key regulatory bodies, each with distinct timelines and priorities:
- EMA (European Medicines Agency): Fast-tracked for review following Tuesday’s regulatory announcement. If approved, the UK’s NHS will face pressure to adopt it, but cost remains a barrier—Ozempic’s list price is £100/month, and this drug may exceed that by 30%.
- FDA (U.S.): Likely to prioritize cardiovascular safety data, given the 2020 SGLT2 inhibitor precedent. A decision could come by mid-2027, but supply chain issues (e.g., Ozempic shortages) may delay rollout.
- WHO (Global South): Unlikely to fast-track without local trial data. 90% of diabetes deaths occur in low- and middle-income countries, yet these regions lack infrastructure for weekly injectables.
The funding source adds another layer of scrutiny. Novo Nordisk, which also markets Ozempic and Wegovy, funded the trial. While this isn’t unusual, it raises questions about conflicts of interest in efficacy claims. A 2023 JAMA analysis found pharma-funded trials of GLP-1 drugs often downplayed long-term risks like thyroid tumors or suicidal ideation. This trial’s 52-week follow-up is too short to detect rare adverse events.
—Dr. Maria Neira, Director of Public Health at the WHO
“We welcome innovations that address the dual burden of diabetes and obesity, but access must be equitable. A drug that costs $500/month in the U.S. won’t solve the crisis in Africa, where 80% of diabetes cases are undiagnosed. We need affordable generics and primary-care integration, not just another patented miracle.”
Side Effects, Contraindications, and Who Should Avoid This Drug
The most common adverse events mirror those of Ozempic/Wegovy: nausea (32% of patients), diarrhea (21%), and constipation (18%). However, the dual-action mechanism may increase the risk of hypoglycemia (low blood sugar) when combined with sulfonylureas or insulin—a critical consideration for 40% of diabetic patients on these medications.
Contraindications & When to Consult a Doctor
- Avoid if you have:
- A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Severe gastrointestinal disease (e.g., gastroparesis, inflammatory bowel disease).
- Pancreatitis or a history of gallbladder issues (GLP-1 drugs increase gallstone risk).
- Seek emergency care if you experience:
- Severe abdominal pain (possible pancreatitis).
- Signs of diabetic ketoacidosis (DKA): nausea, vomiting, rapid breathing, confusion.
- Allergic reactions (rash, swelling, difficulty breathing).
- Special populations:
- Pregnant women: GLP-1 drugs are contraindicated in pregnancy due to potential fetal harm.
- Elderly patients: Higher risk of falls and dehydration from gastrointestinal side effects.
- Pediatric use: Not studied in children; current guidelines restrict GLP-1 drugs to adults.
What Happens Next: The 18-Month Roadmap to Approval (and Beyond)
Here’s the projected timeline based on regulatory filings and expert interviews:
- Q3 2026: EMA’s Committee for Medicinal Products for Human Use (CHMP) issues an opinion. If positive, the drug could enter Europe by early 2027.
- Q1 2027: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee meets to debate cardiovascular safety data. A decision is expected by mid-year.
- 2028: If approved, Novo Nordisk will face patent challenges from generic manufacturers, potentially driving down costs by 2030.
- Long-term (2030+): Real-world data on beta-cell regeneration and cardiovascular outcomes will determine whether this becomes a curative option for early-stage diabetes—or just another expensive treatment.
The bigger question is whether this drug will replace Ozempic/Wegovy or complement them. Given the current shortage of semaglutide, regulators may prioritize approval to alleviate demand. But without addressing the root causes—dietary patterns, physical inactivity, and urbanization—these medications alone won’t curb the epidemic.
References
- The Lancet Diabetes & Endocrinology (2026). “NN9566 in Type 2 Diabetes and Obesity: A Phase 3 Trial.”
- JAMA (2023). “Industry Funding and Reporting of Adverse Events in GLP-1 Trials.”
- FDA Guidance (2020). “Cardiovascular Risk in Diabetes Drug Development.”
- WHO Obesity Fact Sheet (2024).
- CDC Diabetes Statistics (2026).
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting or changing treatments. Drug approval status and efficacy may vary by region.
